GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectorite Biomedical Inc (ROCO:4170) » Definitions » Change In Receivables

Vectorite Biomedical (ROCO:4170) Change In Receivables : NT$0.70 Mil (TTM As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Vectorite Biomedical Change In Receivables?

Vectorite Biomedical's change in receivables for the quarter that ended in Jun. 2024 was NT$1.82 Mil. It means Vectorite Biomedical's Accounts Receivable declined by NT$1.82 Mil from Dec. 2023 to Jun. 2024 .

Vectorite Biomedical's change in receivables for the fiscal year that ended in Dec. 2023 was NT$0.06 Mil. It means Vectorite Biomedical's Accounts Receivable declined by NT$0.06 Mil from Dec. 2022 to Dec. 2023 .

Vectorite Biomedical's Accounts Receivable for the quarter that ended in Jun. 2024 was NT$3.32 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vectorite Biomedical's Days Sales Outstanding for the six months ended in Jun. 2024 was 25.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vectorite Biomedical's liquidation value for the six months ended in Jun. 2024 was NT$181.64 Mil.


Vectorite Biomedical Change In Receivables Historical Data

The historical data trend for Vectorite Biomedical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectorite Biomedical Change In Receivables Chart

Vectorite Biomedical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.94 -0.64 0.78 -3.89 0.06

Vectorite Biomedical Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.00 -2.88 1.18 -1.12 1.82

Vectorite Biomedical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectorite Biomedical  (ROCO:4170) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vectorite Biomedical's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3.323/23.604*91
=25.69

2. In Ben Graham's calculation of liquidation value, Vectorite Biomedical's accounts receivable are only considered to be worth 75% of book value:

Vectorite Biomedical's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=193.285-21.328+0.75 * 3.323+0.5 * 14.386
=181.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectorite Biomedical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vectorite Biomedical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectorite Biomedical Business Description

Traded in Other Exchanges
N/A
Address
Number 97, Section 1, Xintai 5th Road, 6th Floor, Floor-11, Yuzhi District, New Taipei City, Taipei, TWN, 22175
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.

Vectorite Biomedical Headlines

No Headlines